Latest news with #StephanieReisinger
Business Wire
22-05-2025
- Business
- Business Wire
CORRECTING and REPLACING Flatiron Health Announces Research to Be Presented at ASCO 2025
NEW YORK--(BUSINESS WIRE)--Please remove the partners listed under "Real-world (rw) ctDNA testing trends and associated outcomes in patients (pts) with early stage breast cancer (EBC)." Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer. Share The updated release reads: FLATIRON HEALTH ANNOUNCES RESEARCH TO BE PRESENTED AT ASCO 2025 Flatiron's 2025 ASCO research showcases the power of longitudinal, real-world oncology data and innovative AI-driven methodologies to generate actionable evidence, address health equity, and accelerate progress in cancer care and clinical research. Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies exemplify Flatiron's commitment to advancing cancer research and align with this year's ASCO theme, 'Driving Knowledge to Action: Building a Better Future,' by delivering critical evidence to inform and improve patient care. 'AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution,' said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. 'Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.' Highlights include: a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings Schedule a meeting with Flatiron Health at ASCO 2025, and learn more about our abstracts and events, including workshops and panels. Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131. Partners: Memorial Sloan Kettering Cancer Center, AstraZeneca Dana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan Li Genitourinary—Prostate, Testicular, and Penile Poster board: 295 Abstract number: 5096 Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz Maureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav Goyal Quality Care/Health Services Research Poster board: 436 Abstract number: 11097 Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago Jay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya Juloori Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster board: 199 Abstract number: 8078 Molecular residual disease (MRD) in solid tumors Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. Meropol Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster board: 486b Abstract number: TPS3186 Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US) Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. Ryals Online publication only Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists Anosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. Batavia Online publication only A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC) Partner: Incyte Kim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela Munteanu Online publication only A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens Partners: Merck & Co, MSD UK, Mayo Clinic Jennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. Parikh Online publication only Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting Partners: Cleveland Clinic, Merck KGaA, EMD Serono Amanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark Guinter Online publication only Concordance of response-based clinical trial and machine learning–generated real-world end points Partner: Genentech Qianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly Magee Online publication only Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center Hope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky Online publication only Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center Mark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias Jabbour Online publication only About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
Business Wire
22-05-2025
- Business
- Business Wire
Flatiron Health Announces Research to Be Presented at ASCO 2025
NEW YORK--(BUSINESS WIRE)--Flatiron Health today announced 14 abstracts leveraging its high-quality real-world oncology data have been accepted for poster presentation and online publication at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. These studies exemplify Flatiron's commitment to advancing cancer research and align with this year's ASCO theme, 'Driving Knowledge to Action: Building a Better Future,' by delivering critical evidence to inform and improve patient care. Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer. Share 'AI and related technologies have enabled us to unlock data and insights from our entire network of over five million people with cancer, providing unprecedented scale, efficiency, and innovation for both real-world evidence generation and clinical trial execution,' said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. 'Our research accepted at this year's ASCO demonstrates our lasting commitment to deliver actionable evidence and improve care for every person with cancer.' Highlights include: a poster presentation utilizing advanced machine learning models to identify a cohort of over 195,000 to complete the largest real-world study to date examining ctDNA testing in early stage breast cancer an abstract assessing how often PSMA-PET scans were used among non-Latinx/Hispanic White, Black, and Latinx patients with metastatic prostate cancer an abstract demonstrating the potential of a centralized, tech-enabled screening service to make clinical trial enrollment and more efficient, particularly in community oncology settings Schedule a meeting with Flatiron Health at ASCO 2025, and learn more about our abstracts and events, including workshops and panels. Follow Flatiron Health on X and LinkedIn for more updates from #ASCO25 and visit us in person at Booth #11131. Partners: University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado School of Public Health Erin Fidyk, Patrick Ward, Melissa Estevez, Konstantin Krismer, John Ritten, Anca Marinescu, Aaron B. Cohen Breast Cancer—Local/Regional/Adjuvant Poster board: 148 Abstract number: 555 Partners: Memorial Sloan Kettering Cancer Center, AstraZeneca Dana Rathkopf, Danni Zhao, Lana Kovacevic, Jenna Collins, Eunice Hankinson, Helen Marshall, Aaron Springford, Simran Shokar, Helene von Bandemer, Weiyan Li Genitourinary—Prostate, Testicular, and Penile Poster board: 295 Abstract number: 5096 Impact of social determinants of health on mortality in diffuse large B-cell lymphoma (DLBCL) using real-world data Partners: Yale School of Medicine, University of Alabama at Birmingham, Fox Chase Cancer Center, University of Texas Southwestern Medical Center, University of Colorado at Anschutz Maureen Canavan, Mengru Wang, Olive Mbah, Maneet Kaur, Michael J. Hall, Adeel Khan, Jessica McDermott, Madeline Schmitter, Anosheh Afghahi, Gaurav Goyal Quality Care/Health Services Research Poster board: 436 Abstract number: 11097 Partners: UCLA, AstraZeneca, Memorial Sloan Kettering Cancer Center, The University of Chicago Jay Lee, Daniel Simmons, Tiernan Mulrooney, Jeremy Snider, Lana Natalija Kovacevic, Karen Schwed, Aditya Juloori Lung Cancer—Non–Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Poster board: 199 Abstract number: 8078 Molecular residual disease (MRD) in solid tumors Partners: Taylor Cancer Research Center, Exact Sciences, Case Comprehensive Cancer Center Majd T. Ghanim, John Nemunaitis, Tara Marti, Abhishek Dabral, Katherine Diaz-MacInnis, Judith Frederick, Marla Kuleszynski, Yichen Lu, Amanda Rodriguez-Sullivan, Melanie Palomares, Natalie Salituro, Soma Subramaniam, Anthony Tate, Kathleen Turnbull, Neal J. Meropol Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster board: 486b Abstract number: TPS3186 Assessment of racial/ethnic inequities in uptake of Prostate Specific Membrane Antigen - Positron Emission Tomography (PSMA-PET) scans among patients with metastatic prostate cancer in the United States (US) Eunice A. Ochuonyo, Samantha Reiss, Patrick J. Ward, Brooke A. Jarrett, Olive Mbah, Prakirthi Yerram, Laura Rivera-Reyes, Sophia Miller, Kelly Magee, Lynn Rosario, Wendy Wittman, Cleo A. Ryals Online publication only Accrual of racially and ethnically underrepresented populations with multiple myeloma associated with centralized patient screening in a multicenter study Partners: University of Colorado, Johnson & Johnson, New York Cancer and Blood Specialists Anosheh Afghahi, Daniel Sanchez, Yichen Lu, Richard M. Zuniga, Laura Heste, Dina Gifkins, Britney Beaulieu, Catharine Cipolla, Barry Leybovich, Debra Mitchell, Jeffrey Nan, Ebube Onwasigwe, Hemang Patel, Paul Salcuni, Chloe Salzman, Neal J. Meropol, Ashita S. Batavia Online publication only A retrospective real-world study of first-line PD-(L)1 inhibitor use in patients with metastatic non-small cell lung cancer (mNSCLC) Partner: Incyte Kim Saverno, Siobhan Halloran, Mark Guinter, Kelly Magee, Michael Ondovik, J.E. Hamer-Maansson, Mark Cornfeld, Mihaela Munteanu Online publication only A retrospective cohort study of real-world clinical outcomes in patients with CLL/SLL previously treated with covalent BTK inhibitor (cBTKi) and BCL2 inhibitor (BCL2i) regimens Partners: Merck & Co, MSD UK, Mayo Clinic Jennifer Prescott, Christina Parrinello, Ahmed Sawas, Enrico De Nigris, Jing Yang, Erik Bloomquist, Indu Shrivastava, Changxia Shao, Xinyue Liu, Mohammed Farooqui, Sameer A. Parikh Online publication only Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (Tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting Partners: Cleveland Clinic, Merck KGaA, EMD Serono Amanda Nizam, Mairead Kearney, Valerie Morris, Seyed Hamidreza Mahmoudpour, Carroline Lobo, Chiemeka Ike, Jason Hoffman, Ilian Iliev, Prakirthi Yerram, Mark Guinter Online publication only Concordance of response-based clinical trial and machine learning–generated real-world end points Partner: Genentech Qianyi Zhang, Konstantin Krismer, Yichen Lu, Qianyu Yuan, Aaron Dolor, Auriane Blarre, Aaron B. Cohen, Tori Williams, Sophia Maund, Minu K. Srivastava, Kelly Magee Online publication only Partners: Pfizer, University of San Francisco Helen Diller Family Comprehensive Cancer Center, MD Anderson Cancer Center, Dana-Farber Cancer Institute, European Institute of Oncology IRCCS, University of Milano, UPMC Hillman Cancer Center Hope S. Rugo, Rachel M. Layman, Filipa Lynce, Xianchen Liu, Benjamin Li, Lynn McRoy, Aaron B. Cohen, Melissa Estevez, Giuseppe Curigliano, Adam Brufsky Online publication only Unmet need in adults and adolescents and young adults (AYAs) with B-cell acute lymphoblastic leukemia (B-ALL) in the US following a second relapse Partners: Memorial Sloan Kettering Cancer Center, Stanford Cancer Center, AstraZeneca, Tampa General Hospital Cancer Institute, Knight Cancer Institute, MD Anderson Cancer Center Mark B. Geyer, Michaela Liedtke, Vikram Shetty, Anthony Proli, Yazan K Barqawi, Jenna Collins, Nikesh N. Shah, Jessica T. Leonard, Joseph Elias Jabbour Online publication only About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group.
National Post
29-04-2025
- Business
- National Post
Flatiron Health Announces Research to Be Presented at ISPOR 2025
Article content Flatiron's research at this year's conference highlights the ability of scalable, high-quality real-world oncology data and novel rigorous approaches for health outcomes research to support both research and regulatory use cases. Article content NEW YORK — Flatiron Health today announced its presence at ISPOR—The Professional Society for Health Economics and Outcomes Research 2025 Conference, set to take place May 13-16 in Montreal, QC, Canada. Flatiron's real-world data is featured across 15+ pieces of research to be presented at the conference, including eight Flatiron authored research posters. Additionally, Flatiron will participate in a panel discussion on the role of real-world evidence in precision medicine, including how real-world data can be leveraged across international borders to inform regulatory and reimbursement decisions within diverse healthcare systems. Article content 'At this year's ISPOR, Flatiron scientists are using high-quality real-world data to validate novel methodologies that will shape the future of evidence generation and health outcomes research in oncology,' said Stephanie Reisinger, Senior Vice President & General Manager, Real-World Evidence. 'Leveraging innovative AI and machine learning, Flatiron is expanding the utility of global real-world evidence in regulatory decision-making and across a growing range of oncology use cases at an unprecedented scale.' Article content Highlights include: Article content a poster presentation validating the use of ML to extract real-world response from unstructured data in the electronic health records (EHR), offering a scalable and efficient method for generating high-quality oncology real-world data a poster presentation highlighting the acceptance of real-world evidence by the US Food and Drug Administration and the European Medicines Agency, underscoring its potential to complement traditional clinical trial data a poster presentation introducing the Flatiron Health Japan Breast Cancer dataset, a novel, de-identified real-world database derived from structured and unstructured data collected from routine oncology care and stored within EHR systems in Japan Article content Schedule a meeting with Flatiron Health at ISPOR 2025, and learn more about our abstracts and events, including workshops and panels. Article content Follow Flatiron Health on X and LinkedIn for more updates from #ISPORAnnual and visit us in person at Booth #601. Article content Using Regression Discontinuity in Time Design for Real-World Comparative Effectiveness: A Case Study for the Second-Line Use of Pembrolizumab in Advanced Non-Small Cell Lung Cancer Author Affiliations: Flatiron Health, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado School of Public Health Nai-Chia Chen, Antal Zemplenyi, Blythe Adamson, Alex M. Kaizer, Cindy O'Bryant, R. Brett McQueen, Kelly E. Anderson Poster Session 3 Poster Code: MSR87 Article content Performance Assessment and Validation of Real-World Response Data Generated Using a Deep Learning-Based Natural Language Processing Model Across Multiple Solid Tumors Kelly Magee, Qianyu Yuan, Auriane Blarre, Aaron Cohen, Aaron Dolor, Konstantin Krismer, Tori Williams, Cherie Zhang Poster Session 5 Poster Code: MSR142 Article content From Data to Decisions: The Role of Real-World Evidence in Recent Multiple Myeloma Drug Approvals in the US and EU Mamta Parikh, Peter McMahon, Susan Eng, Freda Boateng, Youssef Ghazi, Kerstin Schmidt, Michelle Brockman, Mitch Sierecki Poster Session 5 Poster Code: HPR136 Article content Advancing Breast Cancer Research in Japan Using EHR-Derived Real-World Data Blythe Adamson, Dionne Ng, Harlan Pittel, Arun Sujenthiran, Eri Tajima Poster Session 5 Poster Code: RWD143 Article content Patient Characteristics and Treatment Patterns in Extensive-Stage Small Cell Lung Cancer Author Affiliations: Flatiron Health, Tennessee Oncology, Jazz Pharmaceuticals Wade Iams, Taavy Miller, Samantha Reiss, Navit Naveh, Badri Rengarajan, Amy Nguyen, Kristin J. Moore, Xiaozhou Fan Poster Session 5 Poster Code: HSD69 Article content Augmenting Race and Ethnicity in a Real-World Oncology Cohort Using the Bayesian Improved Surname Geocoding Methodology Gene Ho, Philani Mpofu, Olive Mbah, Cleo Ryals Poster Session 5 Poster Code: MSR136 Article content About Flatiron Flatiron Health is a healthtech company expanding the possibilities for point of care solutions in oncology and using data for good to power smarter care for every person with cancer. Through machine learning and AI, real-world evidence, and breakthroughs in clinical trials, we continue to transform patients' real-life experiences into knowledge and create a more modern, connected oncology ecosystem. Flatiron Health is an independent affiliate of the Roche Group. Article content Article content Article content Article content Article content
